We analyzed high molecular weight polysaccharide (PS) from the Fisher immunotype 2 (IT-2) strain of Pseudomonas aeruginosa for molecular composition and structure, then determined its immunogenicity in healthy adults. The PS was composed of 2-acetamido-2,6-dideoxygalactose (N-acetyl fucosamine) and glucose in a molar ratio of 2:1. Structural analysis by carbon-13 and proton nuclear magnetic resonance confirmed that the high molecular weight PS was structurally identical to that of the 0-specific side chain of the lipopolysaccharide. PS differed from this material in molecular size. Immunization of 19 adult volunteers with doses of 50-100 ,ug of PS resulted in significant rises (P < 0.04-P < 0.0001) in binding antibody levels and killing antibody titers 2 and 4 wk postimmunization. The only reaction to the vaccine was localized tenderness at the immunization site. Analysis of the immunoglobulin isotype response to the vaccine showed a rise in specific serum IgG and IgA antibodies. Heterologous responses to other P. aeruginosa PS antigens were not seen. The antibody levels attained by vaccination were comparable with those in acute-phase serum samples of patients who survived sepsis with IT-2 P. aeruginosa and were significantly higher (P < 0.03) than specific antibody levels in bacteremic patients who died. These results confirm that PS is a high molecular weight, immunogenic form of the P. aeruginosa IT-2 serotype antigen, eliciting levels of type-specific antibody comparable with those seen among patients surviving an episode of P. aeruginosa sepsis.
Introduction
Infections caused by P. aeruginosa may occur during the course of cystic fibrosis and a variety of diseases characterized by a compromised immune system (1, 2) . Not infrequently, P. aeruginosa infections constitute terminal events under these circumstances. Treatment of such infections is often hampered by the severity of the predisposing illness (3, 4) and by the resistance of most strains to multiple antibiotics (5, 6) . Several Receivedfor publication 26 June 1985 and in revisedform 21 October 1985.
(LPS).' Research to date revealed that humoral immune responses after infection with P. aeruginosa are directed at serotype antigens (7, 8) . Animal studies using LPS vaccines have demonstrated a protective effect of type-specific antibody (9) . There is an association between high levels of type-specific antibody in acute-phase serum and survival from P. aeruginosa sepsis (10, 1 1) . Nevertheless, P. aeruginosa LPS vaccines suffer from inherent toxicity ( 12) and a lack of characterization of all of the vaccine components (13) .
We have purified a high molecular weight polysaccharide (PS) component of P. aeruginosa that appears to be a promising material for inducing serotype-specific immunity (14-16). High molecular weight PS is so named because it is serologically and chemically related to the LPS side chain, but it routinely has an average molecular weight of > 100,000. PS lacks detectable lipid or LPS core sugars and is not toxic or pyrogenic in animals (14, 15). The safety and immunogenicity of three different preparations of high molecular weight PS from the immunotype I (IT-1) strain ofP. aeruginosa have previously been demonstrated in humans (17, 18 Vaccine. High molecular weight PS antigen was prepared as previously described in detail (17) . A mannan component was removed from the vaccine as described (18 Chemical analyses. Analyses for nucleic acids, protein, LPS, lipids, and monosaccharide constituents were performed on the vaccine before packaging for human use as described elsewhere (16) . The N-acetyl fucosamine standard used in the gas-liquid chromatographic analysis was a generous gift of Dr 1 1) . Pyrogenicity in rabbits and endotoxin levels (measured by coagulation of a limulus lysate) were measured as previously described (17) .
Volunteers. 20 healthy young adults were recruited to participate in the study through advertising on a bulletin board at a local college. Laboratory personnel were also allowed to participate. A physician obtained informed consent and a briefmedical history from each subject. Subjects were assigned to one ofthree groups to be given different doses of vaccine. 20 ml of blood were obtained by venipuncture before a 0.5-ml subcutaneous injection given in the deltoid region of the arm. Subjects were interviewed 24 and 48 h after the injection to determine reactions, including fever. Postimmunization sera were obtained -2 and 4 wk after injection.
Patient sera. Acute-phase sera from a variety of patients with IT-2 P. aeruginosa sepsis were obtained courtesy of Dr. Lowell Young, University ofCalifornia, Los Angeles, CA; Dr. Matthew Pollock, Uniformed Services University of the Health Sciences, Bethesda, MD; Dr. George Jacoby, Massachusetts General Hospital, Boston, MA; and from patients at the Brigham and Women's Hospital, Boston, MA. Corresponding blood isolates were obtained from the clinical microbiology laboratories and serotyped by agglutination (19) . Survival or death associated with the episode ofP. aeruginosa sepsis was evaluated as described (10) . Clinical characteristics of the patients are described in Table I . Serologic methods. Serum antibody levels to high molecular weight PS from the IT-I through IT-7 strains ofP. aeruginosa were quantitated by use of a radioactive antigen binding (Farr) test as described (16, 17) . Opsonophagocytosis assays were also performed as previously described (17, 22) . Determination of the Ig isotype response to vaccination was evaluated in a radioimmunoprecipitin (RIP) assay as described elsewhere (23) . Statistical methods. Differences in antibody concentrations of preimmunization and postimmunization sera were determined by Student's t test (24) using geometric differences. Opsonophagocytic titers in preimmune and postimmune sera were compared by chi-square analysis.
Antibody concentrations in the sera obtained from patient and volunteer groups were compared by a Mann-Whitney U test (24) .
Results
Chemical analyses. The analyses for various biochemical components and monosaccharide constituents in the IT-2 PS vaccine before packaging for human use are shown in Table II . The preparation was principally carbohydrate, with only trace amounts of proteins, nucleic acids, and lipids. The monosaccharides 2-acetamido-2,6-dideoxygalactose (N-acetyl-fucosamine) and glucose were identified with a molar ratio of 2:1.
Structural analysis. The proton nmr spectrum obtained for the IT-2 high molecular weight PS was identical to those published by two separate groups for the O-specific side chain of the IT-2 P. aeruginosa LPS (24, 25) . The proton nmr spectrum contained signals for two N-acetyl groups at 2.02 and 2.06 parts per million (ppm), two methyl groups at 1.32 ppm, and three anomeric carbons at 4.57, 4.70, and 5.04 ppm. The carbon-1 3 nmr spectrum was identical to that published by Horton et al. (25) Molecular weight. The average molecular weight of the IT-2 PS vaccine before packaging for human use was determined to be 250,000 on a high performance liquid chromatography of 19) . No significant (P > 0.5) differences were noted in antibody levels achieved at 2 wk vs. 4 wk.
An opsonophagocytosis assay was used to measure antibodymediated killing of P. aeruginosa (Table IV) . We determined the titer of each serum required to kill 70% or more of the input inoculum ofbacteria. There was a highly significant (P < 0.001) increase in opsonic killing titer following immunization. The opsonic titers obtained by immunizing with a single dose of PS were comparable with those seen in humans given five to eight doses of a P. aeruginosa LPS vaccine (26) .
The isotypes of antibodies specific to IT-2 PS in pre-and Comparison ofIT-2 PS-specific antibody levels in patients and vaccinates. Pollock and Young (10) have shown that elevated levels of hemagglutinating antibody to LPS in acute-phase serum is associated with survival of P. aeruginosa bacteremia. We examined the concentration of antibody to IT-2 PS in the acute- We believe that the development of an immunogenic form of the 0-specific side chain that can be administered without significant toxicity constitutes a major step towards development of a P. aeruginosa vaccine. Numerous animal studies (9, 27) have demonstrated that antibody specific for serotype antigens such as high molecular weight PS are protective against P. aeruginosa infection. Previous attempts to vaccinate humans with P. aeruginosa LPS were hampered by the toxicity ofthis vaccine (12) . High molecular weight PS apparently is without such toxicity, yet retains the desired immunogenic and serologic properties.
Animal studies have indicated that antibody to the P. aeruginosa serotype antigen is sufficient, by itself, to afford complete protection against bacterial challenge. Mice given a 2.5 cm2 thermal injury are protected against challenge with I07-l0I bacteria following active and passive immunization with PS or antisera to PS (14, 28). An important consequence of our study has been the determination of type-specific antibody levels associated with survival of P. aeruginosa sepsis. Numerous commercial preparations of intravenous IgG are currently being evaluated and marketed, with indications that they may be useful in treating infections with P. aeruginosa (30, 31) . Our finding that survivors had an average type-specific antibody level of 12.8 ug/ml suggests a concentration ofantibody that may need to be achieved in order to assure therapeutic efficacy. Only one of eight patients with antibody levels 2 3.0 ,gg/ml died, while five of six patients with lower concentrations died. Thus 3.0 ,g/ml may be a lower limit of type-specific antibody concentration that possibly gives immunologic protection against P. aeruginosa infections.
Our finding that an IT-2 PS vaccine elicits antibody levels that are comparable with those in bacteremic patients who survive IT-2 P. aeruginosa sepsis suggests that the vaccine may, in fact, offer protection in humans. Interpretation of these data is confounded by the fact that antibody levels in acute-phase sera may be lowered because of antigen release during infection. In addition, numerous host factors contribute to the outcome of P. aeruginosa sepsis, so that elevated antibody titers cannot conclusively be said to have been protective. We did not perform a multiple regression analysis on clinical factors associated with the infections, so variables other than antibody titer may also have contributed to this outcome. In a similar study, however, Pollock and Young (10) did not identify any clinical factors contributing to the outcome of bacteremia other than antibody levels to P. aeruginosa antigens. In our study, one patient with low antibody levels to IT-2 PS survived, whereas the patient with the highest level of antibody died. Clearly, factors other than antibody to PS can be involved in the clinical outcome.
Moreover, we did not analyze serum antibody levels to exotoxin A, as did Pollock and Young (10) and Cross et al. (32) . These studies did show a correlation between survival of P. aeruginosa sepsis and elevated levels of antibody to exotoxin A. The latter study, however, did not control for antibody to serotype antigens, which the former study showed to be correlated with antibody levels to exotoxin A (r = 0.33, P = 0.06) (10). In conclusion, our demonstration of comparable antibody levels in survivors of bacteremia and vaccinates is encouraging but by no means confirms that vaccination with IT-2 PS will be protective.
